The Woodstock based company was awarded B Corp certification after demonstrating strict compliance to the rigorous requirements of this globally-recognised mark.
The studies will allow the company to assess the ability of its next-generation vaccine to boost the immune response against current and potential future strains of COVID-19.
The 745 sq ft molecular diagnostics research and quality control lab will support its customers in developing improved molecular diagnostics for COVID-19 and other pathogens.
The combination expands Exscientia’s capabilities by enabling high content evaluation of individual patient biology in primary tumour tissues rather than artificial cell lines or animal models.
Biotech start-up, DJS Antibodies, is the second company to move into the newly converted class II laboratory space at The Oxford Trust’s Wood Centre for Innovation.
The arrival of G7 health ministers to Oxford on Thursday 03 June will shine a spotlight on Oxfordshire’s considerable achievements in the life sciences sector.
The company has reported robust financial performance in its 2021 unaudited revenues of at least £9.0 million compared to £2.1 million in the 2020 audited accounts.
AstraZeneca has committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021.
The Oxford-based clinical-stage biopharmaceutical company that co-invented a COVID-19 vaccine is a spin-out from Oxford University’s Jenner Institute.
The investment led by Koch Disruptive Technologies helps Sense accelerate its portfolio of products to deliver patient-focused healthcare.
The raise will enable the company to complete development work and gain first in-human data through an early feasibility clinical study.
The company’s technologies and drug-hunting expertise now responsible for the world’s first and second AI-designed drugs to enter Phase I testing.